# A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors.

Source: https://onco.cc/trials/nct07016997/  
OnCo record `nct07016997` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of CBA-1535 run by Chiome Bioscience Inc., now recruiting.

## Summary

A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. is a phase 1 interventional study registered as NCT07016997 by Chiome Bioscience Inc., with 70 participants planned, started 2022-06-27. Conditions recorded: Solid Tumors and Refractory Cancer. Interventions recorded: CBA-1535 and CBA-1535+Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07016997
- Phase: 1
- Setting: A Phase I Study to Assess the Safety, Tolerability and Biomarker Profiles of CBA-1535, Recombinant Protein Tribody in Patients With Previously Treated Advanced Solid Tumors.
- Sponsor: Chiome Bioscience Inc.
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT07016997: https://clinicaltrials.gov/study/NCT07016997

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [CBA-1535](https://onco.cc/drugs/cba-1535/)
- companies: [Chiome Bioscience](https://onco.cc/companies/chiome-bioscience/)

---
JSON: https://onco.cc/api/v1/entities/nct07016997.json